For patients with T3b, T4a and T4b melanoma who qualify for adjuvant therapy, omitting SLNB can be discussed with the patient, but the potential benefits of SLNB in terms of staging (especially in patients with a BRAF-mutated, thick primary stage IIB or IIC who could be upstaged to stage III melanoma) and locoregional control should also be discussed [V, C]. Here, BRAF is linked to melanoma.